title: Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
authors.forename: Noemí
authors.initials: N
authors.lastname: Puig
authors.forename: María D
authors.initials: MD
authors.lastname: Caballero
authors.forename: Miguel
authors.initials: M
authors.lastname: Alcoceba
authors.forename: Elena
authors.initials: E
authors.lastname: Sebastián
authors.forename: Ana
authors.initials: A
authors.lastname: Balanzategui
authors.forename: María E
authors.initials: ME
authors.lastname: Sarasquete
authors.forename: Ramón
authors.initials: R
authors.lastname: García-Sanz
authors.forename: Marcos
authors.initials: M
authors.lastname: González-Díaz
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab